ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 62 of 147 for:    lupus AND Lupus Nephritis

To Compare the Efficacy and Safety of Tripterygium (TW) Versus AZA in the Maintenance Therapy for Lupus Nephritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00881309
Recruitment Status : Completed
First Posted : April 15, 2009
Last Update Posted : May 18, 2011
Sponsor:
Information provided by:
Nanjing University School of Medicine

Brief Summary:

The purpose of this study is to:

  • To access the efficacy of TW compared to Aza in the maintenance therapy for lupus nephritis
  • To investigate the safety and tolerability of TW versus Aza in the maintenance therapy for lupus nephritis

Condition or disease Intervention/treatment Phase
Lupus Nephritis Drug: Tripterygium Not Applicable

Detailed Description:
Tripterygium (TW) is a Chinese traditional patent drugs in treating chronic glomerulonephritis. It has been used to treat lupus nephritis for many years with less side effects. We compare the efficacy and safety of TW vs Aza in the maintenance therapy of lupus nephritis.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: To Compare the Efficacy and Safety of Tripterygium (TW) vs Aza in the Maintenance Therapy for Lupus Nephritis
Study Start Date : March 2009
Actual Primary Completion Date : April 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: immunosuppressor Drug: Tripterygium
TW 90mg/d




Primary Outcome Measures :
  1. complete remission rate [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. renal relapse [ Time Frame: 2 years ]
  2. partial remission [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients who signed written informed consent form;
  2. SLE patient, aged between 18-60 years, female or male;
  3. Patients diagnosed lupus nephritis according to ISN/RPS 2003 classification criteria, class Ⅲ, Ⅳ,Ⅳ+Ⅴ, Ⅲ+Ⅴ or Ⅴ LN by renal biopsy;
  4. All patients received induction therapy for 6-12 months, including MMF, CTX, FK506 or multi-target therapy;
  5. When recruited in the study, patients received partial remission or complete remission for 3 months;

    • Complete remission: proteinuria < 0.4 g/24h, negative urine sediment, serum albumin > 35 g/L, elevated scr < 0.3 mg/dl, no extra-renal complications;
    • Partial remission: proteinuria < 1.0 g/24h, urine RBC < 500000/ml without casts, serum albumin > 35 g/L, elevated scr <0.3 mg/dl, no extra-renal complications.

Exclusion Criteria:

  1. Patients who didn't sign written informed consent form or could not obey the protocol;
  2. Patients who didn't received the CR or PR criterion;
  3. Patients who have impaired liver function, with ALT/GPT or AST/GOT twice more than the normal upper limit;
  4. WBC < 3000/mm3 in peripheral blood;
  5. Patients with abnormal of central nervous system.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00881309


Locations
China, Jiangsu
Research Institute of Nephrology,Jinling Hospital
Nanjing, Jiangsu, China, 210002
Sponsors and Collaborators
Nanjing University School of Medicine
Investigators
Principal Investigator: Weixin Hu, Doctor Nanjing University School of Medicine

Responsible Party: Weixin Hu, Nanjing University School of Medicine
ClinicalTrials.gov Identifier: NCT00881309     History of Changes
Other Study ID Numbers: NJCT-0902
First Posted: April 15, 2009    Key Record Dates
Last Update Posted: May 18, 2011
Last Verified: April 2009

Additional relevant MeSH terms:
Nephritis
Lupus Nephritis
Kidney Diseases
Urologic Diseases
Glomerulonephritis
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases